US007659302B2

(12) **United States Patent**
Muller et al.

(10) **Patent No.: US 7,659,302 B2**
(45) **Date of Patent: Feb. 9, 2010**

(54) **METHODS OF USING (+)-2-[1-(3-ETHOXY-4 METHOXYPHENYL)-2-METHYLSULFONYL-ETHYL]-4 ACETYLAMINOISOINDOLINE 1,3-DIONE**

(75) Inventors: **George W. Muller**, Bridgewater, NJ (US); **Peter H. Schafer**, Somerset, NJ (US); **Hon-Wah Man**, Princeton, NJ (US); **Chuansheng Ge**, Belle Mead, NJ (US)

(73) Assignee: **Celgene Corporation**, Summit, NJ (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **12/069,282**

(22) Filed: **Feb. 8, 2008**

(65) **Prior Publication Data**

US 2008/0207730 A1 Aug. 28, 2008

Related U.S. Application Data

(62) Division of application No. 11/170,308, filed on Jun. 28, 2005, now Pat. No. 7,358,272, which is a division of application No. 10/392,195, filed on Mar. 19, 2003, now Pat. No. 6,962,940.

(60) Provisional application No. 60/366,515, filed on Mar. 20, 2002, provisional application No. 60/438,450, filed on Jan. 7, 2003.

(51) **Int. Cl.**
A61K 31/4035 (2006.01)
C07D 209/44 (2006.01)

(52) **U.S. Cl.** **514/417**; 548/469; 548/478

(58) **Field of Classification Search** 548/469, 548/478; 514/417
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,031,450	A	4/1962	Fischer et al.	
3,322,755	A	5/1967	Roch et al.	
3,920,636	A	11/1975	Takahashi et al.	
4,001,237	A	1/1977	Partyka et al.	
4,001,238	A	1/1977	Partyka et al.	
4,047,404	A	9/1977	Hayashi	
4,060,615	A	11/1977	Matier et al.	
4,101,548	A	7/1978	Crenshaw et al.	
4,162,316	A	7/1979	Nishimura et al.	
4,209,623	A	6/1980	Juby	
4,880,810	A	11/1989	Lowe, III	
4,885,301	A	12/1989	Coates	
5,147,875	A	9/1992	Coates et al.	
5,354,571	A	10/1994	Morikawa et al.	
5,401,774	A	3/1995	Pamukcu et al.	
5,439,895	A	8/1995	Lee et al.	
5,488,055	A	1/1996	Kumar et al.	
5,608,914	A	3/1997	Keesler	
5,614,530	A	3/1997	Kumar et al.	
5,614,627	A	3/1997	Takase et al.	
5,658,940	A	8/1997	Muller et al.	
5,698,579	A	12/1997	Muller	
5,703,098	A	12/1997	Muller et al.	
5,710,170	A	1/1998	Guay et al.	
5,728,844	A	3/1998	Muller et al.	
5,728,845	A	3/1998	Muller et al.	
5,736,570	A	4/1998	Muller et al.	
5,798,373	A	8/1998	Warrellow	
5,801,195	A	9/1998	Muller et al.	
5,849,770	A	12/1998	Head et al.	
5,877,200	A	3/1999	Muller	
5,891,896	A	4/1999	Warrellow et al.	
6,011,050	A	1/2000	Muller et al.	
6,020,339	A	2/2000	Perrier et al.	
6,020,358	A	2/2000	Muller et al.	
6,034,089	A	3/2000	Han et al.	
6,046,221	A	4/2000	Muller et al.	
6,069,156	A	5/2000	Oku et al.	
6,162,830	A	12/2000	Connor et al.	
6,166,041	A	12/2000	Cavalla et al.	
6,177,471	B1	1/2001	Menander et al.	
6,204,275	B1	3/2001	Friesen et al.	
6,218,400	B1	4/2001	Daugan et al.	
6,300,335	B1	10/2001	Campbell et al.	
6,316,472	B1	11/2001	Frenette et al.	
6,333,354	B1	12/2001	Schudt	
6,962,940	B2 *	11/2005	Muller et al.	514/417
7,208,516	B2 *	4/2007	Muller et al.	514/417
7,276,529	B2 *	10/2007	Muller et al.	514/417
7,358,272	B2 *	4/2008	Muller et al.	514/417
7,427,638	B2 *	9/2008	Muller et al.	514/411
7,507,759	B2 *	3/2009	Muller et al.	514/417

FOREIGN PATENT DOCUMENTS

EP	0 347 146	6/1989
EP	0 349 239 A2	6/1989
EP	0 351 058	6/1989
EP	0 352 960 A2	7/1989
EP	0 395 328	4/1990
EP	0 428 268 A2	10/1990
EP	0 463 756 A1	6/1991
EP	0 526 004 A1	7/1992

(Continued)

OTHER PUBLICATIONS

U.S. Appl. No. 60/454,155, filed Mar. 12, 2003, Muller, G. et al.

(Continued)

Primary Examiner—Golam M Shameem
(74) *Attorney, Agent, or Firm*—Jones Day

(57) **ABSTRACT**

Stereomerically pure (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, substantially free of its (−) isomer, and prodrugs, metabolites, polymorphs, salts, solvates, hydrates, and clathrates thereof are discussed. Also discussed are methods of using and pharmaceutical compositions comprising the (+) enantiomer of 2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione are disclosed. The methods include methods of treating and/or preventing disorders ameliorated by the reduction of levels of TNF-α or the inhibition of PDE4.

20 Claims, 2 Drawing Sheets